Premium
Intensity‐modulated radiotherapy or volumetric‐modulated arc therapy in patients with head and neck cancer: Focus on salivary glands dosimetry
Author(s) -
Vallard Alexis,
Guy JeanBaptiste,
Mengue Ndong Sylvie,
Vial Nicolas,
Rivoirard Romain,
Auberdiac Pierre,
Méry Benoîte,
Langrand–Escure Julien,
Espenel Sophie,
Moncharmont Coralie,
Ben Mrad Majed,
Diao Peng,
Goyet Dominique,
Magné Nicolas
Publication year - 2016
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.24398
Subject(s) - medicine , dosimetry , radiation therapy , head and neck cancer , nuclear medicine , head and neck , salivary gland , cancer , head and neck squamous cell carcinoma , radiology , surgery
Abstract Background Despite radiotherapy (RT) technical improvements, high salivary dysfunction rates are still reported in patients with head and neck squamous cell carcinoma (HNSCC). The purpose of the present study was to report salivary glands dosimetry with volumetric‐modulated arc therapy (VMAT) and intensity‐modulated RT (IMRT). Methods Dosimetry of consecutive patients receiving IMRT or VMAT for proven HNSCC between 2007 and 2013 were retrospectively reviewed. Results Data of 609 patients were studied. Mean dose, mean maximum dose, and mean percentage of salivary gland volume receiving at least 26 Gy (V26) of the contralateral parotid were 24.50 Gy (range, 0–70.4 Gy), 39.08 Gy (range, 0.38–76.45 Gy), and 40.92% (range, 0% to 100%), respectively. Mean and maximum dose on contralateral submandibular gland were 48.18 Gy (range, 0.19–70.73 Gy), and 61.25 Gy (range, 0–75.8 Gy), respectively. Conclusion Target volume coverage still has to be prioritized over organs at risk (OAR) sparing with new RT techniques. Submandibular glands are not sufficiently taken into account in guidelines. © 2016 Wiley Periodicals, Inc. Head Neck 38: 1028–1034, 2016